Tidal Investments LLC Purchases 29,283 Shares of Sanofi $SNY

Tidal Investments LLC boosted its position in Sanofi (NASDAQ:SNY – Free Report) by 21.5% during the second quarter, Holdings Channel reports. The institutional investor owned 165,289 shares of the company’s stock after purchasing an additional 29,283 shares during the quarter. Tidal Investments LLC’s holdings in Sanofi were worth $7,051,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. boosted its position in Sanofi by 81.3% during the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after acquiring an additional 2,635,867 shares during the last quarter. Capital Research Global Investors acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $79,960,000. Morgan Stanley lifted its position in shares of Sanofi by 20.4% in the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after purchasing an additional 1,540,271 shares in the last quarter. Manning & Napier Advisors LLC lifted its position in shares of Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after purchasing an additional 1,194,141 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Sanofi by 29.7% during the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after purchasing an additional 1,168,339 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Get Sanofi alerts:

Sanofi Stock Up 0.1%

Shares of SNY stock opened at $42.77 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The firm’s 50-day moving average is $43.95 and its 200-day moving average is $44.58. The stock has a market cap of $103.69 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 1.29 and a beta of 0.35. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68.

Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.24 EPS. Sell-side analysts predict that Sanofi will post 5.07 EPS for the current year.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Thursday. Royal Bank Of Canada initiated coverage on shares of Sanofi in a research note on Tuesday. They set a “sector perform” rating for the company. Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Finally, Morgan Stanley set a $49.00 target price on Sanofi in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $49.50.

View Our Latest Report on SNY

About Sanofi

(Free Report)

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.

Further Reading

• Five stocks we like better than Sanofi
• Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
• Optical Cable Corporation Is Starting to Get the Market’s Attention
• Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
• Is Nike’s Index Demotion a Warning or a Buying Opportunity?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.